MARKET

ENGN

ENGN

enGene Therapeutics Inc
NASDAQ
1.780
+0.020
+1.14%
After Hours: 1.790 +0.01 +0.56% 19:23 07/02 EDT
OPEN
1.790
PREV CLOSE
1.760
HIGH
1.810
LOW
1.755
VOLUME
588.35K
TURNOVER
--
52 WEEK HIGH
12.25
52 WEEK LOW
1.400
MARKET CAP
119.24M
P/E (TTM)
-0.8164
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ENGN last week (0622-0626)?
Weekly Report · 6d ago
Weekly Report: what happened at ENGN last week (0615-0619)?
Weekly Report · 06/22 09:11
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
NASDAQ · 06/19 09:09
enGene amends filing, lifts estimated non-cash stock-comp restructuring charge to $4.7 million-$5 million
PUBT · 06/18 20:07
Midday Fly By: Trump says Apple working with Intel to design chips
TipRanks · 06/18 16:22
This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Benzinga · 06/18 12:10
enGene Holdings Cut to Underweight From Equal-Weight by Morgan Stanley
Dow Jones · 06/18 10:59
Morgan Stanley Downgrades enGene Therapeutics to Underweight
Benzinga · 06/18 10:48
More
About ENGN
enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).

Webull offers enGene Therapeutics Inc stock information, including NASDAQ: ENGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENGN stock methods without spending real money on the virtual paper trading platform.